Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: A multivariate analysis of 116 patients

Annals of Saudi Medicine

Volumn 32, Issue 3, 2012, Pages 250-255

  Okumus, Nilgun Ozbek ^a   Gursel, Bilge ^a   Meydan, Deniz ^a   Ozdemir, Ozge ^a   Odabasi, Eylem ^a   Gonullu, Guzin ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; SEIZURE; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84865506233     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.5144/0256-4947.2012.250     Document Type: Article

References (33)

1. Combs SE, Gutwein S, Schulz-Ertner D, Kampen MV, Thilmann C, Edler L, et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Strahlenther Onkol 2005;181:372-7. (Pubitemid 40875261)
2. Back MF, Ang EL, Ng WH, See SJ, Lim CC, Chan SP, et al. Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy. Ann Acad Med Singapore 2007;36:338-42. (Pubitemid 47121447)
3. Jalali R, Basu A, Gupta T, Munshi A, Menon H, Sarin R, et al. Encouraging experience of concomitant temozolomide with radiotherapy followed by adjuvant temozolomide in newly diagnosed glioblastoma multiforme: Single institution experieance. Br J Neurosurg 2007;21:583-7. (Pubitemid 350249205)
4. Stupp R, Mason WP, Van Den Brent MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
5. Narayana A, Recht L, Gutin PH. Central nervous system tumors. In: Hoppe RT, Phillips TL, Roach M, editors. Textbook of Radiation Oncology. 3rd ed. Philadelphia: Elsevier Saunders; 2010. p. 421-45.
6. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomized phase II study of temozolamide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005;23:2372-7. (Pubitemid 46218731)
7. Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G, Vecht C. Glioblastoma in adults. Crit Rev Oncol Hematol 2008;67:139-52.
8. Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, et al. Primary glioblastoma multiforme in younger patients: A single-institution experience. Tumori 2006;92:407-11. (Pubitemid 44861776)
9. Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, et al. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori 2007;93:248-56. (Pubitemid 47080010)
10. Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 2001;52:161-71. (Pubitemid 32691179)
11. Nakagawa K, Aoki Y, Fujimaki T, Tago M, Terahara A, Karasawa K, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998;40:1141-9. (Pubitemid 28152930)
12. Salcman M. Supratentorial gliomas: Clinical features and surgical therapy. In: Wilkins RH, Rengachary SS, editors. Neurosurgery. New York: McGraw-Hill; 1985. p. 579-90.
13. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-10. (Pubitemid 23133591)
14. McKeran RO, Thomas DG. The clinical study of gliomas. In: Thomas DG, Graham DI, editors. In Brain Tumors: Scientific Basis, Clinical Investigation, and Current Therapy. London: Butterworth; 1980. p. 194-230.
15. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 1989;71:487- 93. (Pubitemid 19244261)
16. Miller PJ, Hassanein RS, Giri S, Kimler GF, O'Boynick P, Evans RG . Univariate and multivariate statistical analysis of high-grade gliomas: The relationship of radiation dose and other prognostic factors. Int J Radiat Oncol Biol Phys 1990;19:275-80. (Pubitemid 20299018)
17. Mineo JF, Bordron A, Baroncini M, Ramirez C, Maurage CA, Blond S, et al. Prognosis factors of survival time in patients with glioblastoma multiforme: A multivariate analysis of 340 patients. Acta Neurochir (Wien) 2007;149:245-53.
18. Ozbek N, Cakir S, Gursel B, Meydan D. Prognostic significance of seizure in patients with glioblastoma multiforme. Neurol India 2004;52:76- 8.
19. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al. Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. Neurosurgery 2008;62:564-76.
20. Fiveash JB, Nordal RA, Markert JM, Ahmed RS, Nabors LB. High-grade gliomas. In: Gunderson LL, Tepper JE, editors. Clinical Radiation Oncology. 2nd ed. Philadelphia: Churcill-Livingstone; 2007. p. 515-37.
21. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, DeMonte F, Lang FF, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-8. (Pubitemid 32799739)
22. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ; ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392-401.
23. Pichlmeier U, Bink A, Schackert G, Stummer W; ALA Glioma Study Group. Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 2008;10:1025-34.
24. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-31. (Pubitemid 10187518)
25. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991;64:769-74.
26. Nelson DF, Diener-West M, Horton J, Chang CH, Schoenfeld D, Nelson JS. Combined modality approach to treatment of milignant gliomasre- evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: A joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988;6:279-84. (Pubitemid 18048001)
27. Tanaka M, Ino Y, Nakagawa K, Tago M, Todo T. High-dose conformal radiotherapy for supratentorial malignant glioma: A historical comparison. Lancet Oncol 2005;6:953-60. (Pubitemid 41685228)
28. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585- 97. (Pubitemid 23100496)
29. Stewart LA. Chemotherapy in adult highgrade glioma: A systematic review and metaanalysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8. (Pubitemid 34286538)
30. Hirose Y, Berger MS, Pieper RO. p53 Effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001;61:1957-63. (Pubitemid 32692013)
31. Stupp R, Dietrich PY, Kraljevic SO, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82. (Pubitemid 34177445)
32. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase II study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
33. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453-61. (Pubitemid 351597795)